OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Rafii on Future Immunotherapy Approaches for Patients With Bladder Cancer

September 2nd 2016

Saeed Rafii, MD, PhD, medical director, Sarah Cannon Research Institute, United Kingdom, discusses novel immunotherapy approaches for the treatment of patients with bladder cancer.

Dr. Blute on Kidney-Sparing Surgery Vs Radical Nephrectomy in RCC

September 1st 2016

Michael L. Blute, MD, chair of Department of Urology, Massachusetts General Hospital, discusses the differences between kidney-sparing surgery and radical nephrectomy for patients with renal cell carcinoma (RCC).

Dr. Sharma on Tolerability of SIRT in Patients With CRC

September 1st 2016

Dr. Navesh K. Sharma, associate professor of Radiology in the Division of Radiology and Oncology at Penn State Hershey Medical Center and section chief of Radiation Oncology at the Penn State Health St. Joseph Cancer Center, discusses the safety profile of selective internal radiation therapy (SIRT) when added to chemotherapy for patients with colorectal cancer (CRC) that has metastasized to the liver.

Dr. Areej El-Jawahri on the Impact of Palliative Care

September 1st 2016

Dr. Barbara J. Gitlitz on Why PD-L1 is Not a Good Biomarker for Immunotherapy in Lung Cancer

September 1st 2016

Dr. Kathy S. Albain on Breast Cancer Risk After 5 Years of Tamoxifen

September 1st 2016

Dr. White on Relationship Between Multigene Assays and RT in Breast Cancer

September 1st 2016

Julia White, MD, professor of Radiation Oncology, Ohio State University Comprehensive Cancer Center, discusses the relationship between multigene assays and radiation therapy in patients with breast cancer.

Dr. Pennell on Importance of EGFR Testing in NSCLC

August 31st 2016

Nathan Pennell, MD, PhD, associate professor of Medicine at Cleveland Clinic, discusses the importance of testing patients with non–small cell lung cancer (NSCLC) to determine if they harbor the EGFR mutation, as well as the agents available to target that genetic abnormality.

Dr. Leora Horn on Toxicities With Immunotherapy in Lung Cancer

August 31st 2016

Dr. Anderson on Future Treatment Landscape of Multiple Myeloma

August 30th 2016

Kenneth C. Anderson, MD, a 2014 Giant of Cancer Care in Myeloma, program director, Jerome Lipper Multiple Myeloma Center and LeBow Institute for Myeloma Therapeutics, institute physician, Dana-Farber Cancer Institute/Brigham and Women's Cancer Center, discusses how currently available agents will continue to impact the field of multiple myeloma.

Dr. O'Connor on Ongoing Breast Cancer Research

August 30th 2016

Kathleen L. O'Connor, MD, professor, associate director of Cancer Education, Department of Molecular and Cellular Biochemistry, University of Kentucky Markey Cancer Center, discusses the ongoing research in the field of breast cancer.

Dr. Giorgio Scagliotti on Taking a Targeted Approach to Immunotherapy in Lung Cancer

August 30th 2016

Dr. Julio Pow-Sang on Options for Low-and Intermediate-Risk Prostate Cancer

August 30th 2016

Dr. Chandarlapaty on Role of the PI3K Pathway in Breast Cancer

August 29th 2016

Sarat Chandarlapaty, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the role of the PI3k pathway in patients with metastatic breast cancer.

Dr. Nanus on Clinical Trials Exploring Immunotherapy in Bladder Cancer

August 29th 2016

David M. Nanus, MD, medical oncologist, Weill Cornell Medicine and NewYork-Presbyterian Hospital, discusses ongoing clinical trials exploring immunotherapy agents for the treatment of patients with bladder cancer.

Dr. Robert Coleman on BRCA Testing in Ovarian Cancer

August 27th 2016

Dr. Michael Brawer on Predicting Prostate Cancer Aggressiveness

August 27th 2016

Dr. Poch on Nivolumab as a Treatment for Patients With Bladder Cancer

August 26th 2016

Michael A. Poch, MD, urologist and assistant member at Moffitt Cancer Center, discusses the potential of nivolumab (Opdivo) as a treatment for patients with metastatic bladder cancer.

Dr. Hays on Targeting Mutations in Gynecologic Cancers

August 26th 2016

John Hays, MD, assistant professor of Internal Medicine, Ohio State University Comprehensive Cancer Center, discusses how researchers are actively exploring how to target rarer mutations in patients with a variety of gynecologic cancers.

Dr. Matthew Yurgelun on Next Steps in Understanding CRC Mutations

August 26th 2016